{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:58:06Z","timestamp":1773061086992,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","interventional.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.iccl.2020.06.002","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T07:39:11Z","timestamp":1597390751000},"page":"441-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients"],"prefix":"10.1016","volume":"9","author":[{"given":"Matthew J.","family":"Price","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.iccl.2020.06.002_bib1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jacc.2015.02.004","article-title":"The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: chasing a mirage","volume":"65","author":"Price","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.iccl.2020.06.002_bib2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A\u00a0clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators","volume":"339","author":"Leon","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.iccl.2020.06.002_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2020.06.002_bib4","first-page":"35","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"383","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.iccl.2020.06.002_bib5","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.iccl.2020.06.002_bib6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.iccl.2020.06.002_bib7","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.iccl.2020.06.002_bib8","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-17-00720","article-title":"2-year outcomes of high bleeding risk patients with acute coronary syndrome after biolimus-A9 polymer-free drug-coated stents: a leaders free sub-study","author":"Jensen","year":"2018","journal-title":"EuroIntervention"},{"issue":"7","key":"10.1016\/j.iccl.2020.06.002_bib9","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.amjcard.2016.06.061","article-title":"Trends in bare-metal stent use in the United States in patients aged \u226565 years (from the CathPCI REGISTRY)","volume":"118","author":"Rymer","year":"2016","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.iccl.2020.06.002_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/clc.22693","article-title":"Predictors and variability of drug-eluting vs bare-metal stent selection in contemporary percutaneous coronary intervention: insights from the PRISM study","volume":"40","author":"Shafiq","year":"2017","journal-title":"Clin Cardiol"},{"issue":"8","key":"10.1016\/j.iccl.2020.06.002_bib11","doi-asserted-by":"crossref","first-page":"e005280","DOI":"10.1161\/JAHA.116.005280","article-title":"Selection of stent type in patients with atrial fibrillation presenting with acute myocardial infarction: an analysis from the ACTION (acute coronary treatment and intervention outcomes network) registry-get with the guidelines","volume":"6","author":"Vora","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"21","key":"10.1016\/j.iccl.2020.06.002_bib12","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.iccl.2020.06.002_bib13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.iccl.2020.06.002_bib14","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1910021","article-title":"Polymer-based or polymer-free stents in patients at high bleeding risk","volume":"382","author":"Windecker","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.iccl.2020.06.002_bib15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","article-title":"Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?","volume":"109","author":"Virmani","year":"2004","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.iccl.2020.06.002_bib16","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1161\/01.CIR.94.7.1690","article-title":"Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries","volume":"94","author":"van der Giessen","year":"1996","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.iccl.2020.06.002_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCINTERVENTIONS.109.877522","article-title":"Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model","volume":"3","author":"Tada","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"10.1016\/j.iccl.2020.06.002_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jcin.2015.09.008","article-title":"Polymer-free biolimus A9-coated stents in the treatment of De Novo coronary lesions: 4- and 12-month angiographic follow-up and final 5-year clinical outcomes of the prospective, multicenter BioFreedom FIM clinical trial","volume":"9","author":"Costa","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"16","key":"10.1016\/j.iccl.2020.06.002_bib19","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.iccl.2020.06.002_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2016.10.009","article-title":"2-year outcomes of high bleeding risk patients after polymer-free drug-coated stents","volume":"69","author":"Garot","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"29","key":"10.1016\/j.iccl.2020.06.002_bib21","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/eurheartj\/ehu026","article-title":"Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation","volume":"35","author":"Silber","year":"2014","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.iccl.2020.06.002_bib22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jcin.2017.05.004","article-title":"First report of the resolute Onyx 2.0-mm zotarolimus-eluting stent for the treatment of coronary lesions with very small reference vessel diameter","volume":"10","author":"Price","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.iccl.2020.06.002_bib23","first-page":"253","article-title":"Safety and efficacy of the next generation resolute Onyx zotarolimus-eluting stent: primary outcome of the RESOLUTE ONYX core trial","volume":"92","author":"Price","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.iccl.2020.06.002_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ahj.2019.04.017","article-title":"Rationale and design of the Onyx ONE global randomized trial: a randomized controlled trial of high-bleeding risk patients after stent placement with 1month of dual antiplatelet therapy","volume":"214","author":"Kedhi","year":"2019","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.iccl.2020.06.002_bib25","first-page":"143","article-title":"Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study","volume":"15","author":"Roleder","year":"2019","journal-title":"Postepy Kardiol Interwencyjnej"},{"issue":"16","key":"10.1016\/j.iccl.2020.06.002_bib26","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"issue":"10073","key":"10.1016\/j.iccl.2020.06.002_bib27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745820300432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745820300432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:58:26Z","timestamp":1761933506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745820300432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2211745820300432"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2020.06.002","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2020.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}